e18002 Background: Most patients with adult ALL eventually relapse. Salvage regimens in these patients and in patients with primary refractory disease are generally based on cytarabine in combination with other agents. Exact merit of each combination remains undefined as these continue to be tested in non randomized trials. This study was conducted with the objectives to find out the efficacy and toxicity of cytarabine and idarubicin combination. Methods: From December 2006 to March 2008, 30 patients were enrolled in this prospective, nonrandomized single institution phase II feasibility study. It was empirically decided that the study will only be considered feasible if more then ten patients achieve a complete remission. Patients who relapsed during maintenance therapy or were refractory and were at least 16-years-old were considered eligible provided they have received at least vincristine and prednisone as induction. No prior cytarabine was allowed. Cytarabine 100 mg/m2 continuous infusion for seven days along with idarubicin 12 mg/m2 day 1 to 3, IV bolus was given. Bone marrow examination was done 15 days after the completion of chemotherapy. Results: All thirty patients completed planned treatment. Five patients died of infection during treatment. Eleven patients achieved complete remission. All patients relapsed within eight months. Conclusions: The regimen of cytrarabine and idarubicin is feasible and sufficiently effective in relapsed or refractory adult ALL with manageable toxicity. No significant financial relationships to disclose.
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma
